Morepen Laboratories Ltd. Share Price

Symbiotec Pharmalab

• Symbiotec Pharmalab is coming out with a 100% book building; initial public offering (IPO) of 1,87,34,736 shares of face value Rs 2 each in a price band Rs 938-988 per equity share. 
• Not more than 50% of the issue will be allocated to Qualified Institutional Buyers (QIBs), including 5% to the mutual funds. Further, not less than 15% of the issue will be available for the non-institutional bidders and the remaining 35% for the retail investors.
• The issue will open for subscription on August 24, 2026 and will close on August 27, 2026.
• The shares will be listed on BSE as well as NSE.
• The face value of the share is Rs 2 and is priced 469 times of its face value on the lower side and 494 times on the higher side.
• Book running lead managers to the issue are JM Financial, Avendus Capital, Motilal Oswal Investment Advisors and Nomura Financial Advisory and Securities (India).
• Compliance officer for the issue is Salil Jain. 

Profile of the company

The company is a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across three platforms- organic chemistry, biotechnology and complex injectables. It has a global leadership position in corticosteroid and steroidal-hormone active pharmaceutical ingredients (APIs). The company is the only Indian and global company to have a presence across the top 10 corticosteroid and steroidal-hormone APIs demonstrating the depth of its portfolio. It manufactures these products using fermentation and multi-step complex chemical reactions.

With over 30 years of industry experience, it has evolved from a labscale steroidal-hormone API manufacturer in 1995 into an industrial-scale, backward-integrated platform with approvals from the United States Food and Drug Administration (USFDA), European Union Good Manufacturing Practices (EU-GMP), Ministry of Food and Drug Safety, Korea and other global organisations. It has leveraged its deep capabilities across organic chemistry, biotechnology, and complex injectables to operate as a contract development and manufacturing organisation (CDMO) variably for specialty pharmaceutical and nutraceutical companies globally, offering products and services across the three platforms in which it also manufactures its own products.

The company has a robust product portfolio of over 60 corticosteroid and steroidal-hormone APIs that are supplied globally, including Hydrocortisones, Betamethasones, Methylprednisolones, Progesterones, Estrogens and Testosterones, which are used extensively in critical care setups, as well as across chronic therapeutic areas such as respiratory, dermatology, pain management, oncology and gynaecology. Its capabilities span three interlinked platforms: (i) organic chemistry, including flow chemistry, hydrogenation, and photochemistry; (ii) biotechnology, including biosynthesis and biotransformation, and recombinant biologics, including Glucagon-like Peptide-1 (GLP-1) and Insulins; and (iii) forward integration into complex injectables including double-chamber vials, double-chamber bags and double-chamber syringes, collectively enabling it to commercialise and scale hard-to-replicate products and services.

Proceed is being used for: 

• Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the company
• General corporate purposes

Industry overview

India has been aptly crowned the Pharmacy of the World, particularly for its manufacturing prowess and contributions to the global pharma sector. India is the largest provider of generic medicines worldwide, holding a 20% share in global supply by volume, encompassing a diverse range of 60,000 generic brands across 60 therapeutic categories. The industry's global reach is underscored by the fact that India exports pharmaceuticals to over 200 countries, supplying more than 50% of Africa's generic medicine needs, almost 40% of the generic demand in the US, and approximately 25% of all medicines in the UK.

India is among the largest global exporters of APIs, supported by efficient processes, regulatory expertise, scale, and cost advantages. API exports grew from $4.2 billion in 2020 to $4.9 billion in 2025, a CAGR of 3.1%, despite increased domestic consumption as local manufacturers supply more to Indian formulation companies. Exports are projected to reach $6.4 billion by 2030, reflecting a 5.5% CAGR from 2025 to 2030. Exports to regulated markets rose from $1.9 billion in 2020 to $2.3 billion in 2025 (3.9% CAGR) and are expected to reach $3.2 billion by 2030. Exports to emerging markets increased from $2.3 billion to $2.6 billion (2.5% CAGR) between 2020 and 2025 and are projected to reach $3.2 billion by 2030 (4.2% CAGR).

India’s deep-rooted credibility in highly regulated markets illuminates its end-to-end manufacturing competence. In Q1 2025, Indian companies accounted for 48% of all USDMF49 submissions. Additionally, in 2025, Indian companies operated more than 220 US FDA-approved API manufacturing facilities, significantly outpacing counterparts in the US and China. Additionally, India had 156 facilities approved for either formulations or formulations plus APIs, demonstrating its manufacturing capabilities50. This regulatory proficiency enables India to meet the global demand for APIs and FDFs seamlessly, offering a reliable, high-quality, and scalable supply base across various therapeutic categories.

Pros and strengths 

Long-standing relationships with domestic and global customer base: As of March 31, 2026, it served over 200 customers across more than 40 countries, supported by its strong focus on quality assurance, scale of operations and ability to ensure consistent supply of complex APIs. its customer portfolio comprises key generic and specialty pharmaceutical companies in global markets such as North America, Europe, and Asia, including several pharmaceutical majors and formulations companies. As of March 31, 2026, it had over 50 domestic customers and over 150 export customers. It has consistently added new customers over the last three Fiscals, contributing to continued expansion of its commercial footprint. In the Fiscals 2026, 2025 and 2024, it added 101, 96, and 89 new distinct customers.

Fully-invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and clean regulatory track record: The company had two operational industrial-scale API manufacturing facilities and had commissioned two additional manufacturing facilities, leading to an aggregate maximum chemical synthesis capacity of 584.67 MT, fermentation capacity of 700 KL, and complex injectables capacity of 20 million vials. In addition, it is in the process of expanding its biologics capacity by adding a dedicated 14 KL (comprising two reactors of 7 KL each) fermentation capacity for biologics manufacturing at its proposed Biologics Facility in Ujjain, to cater to the increasing demand for GLP-1 and Insulin. As of March 31, 2026, it was among the few players in India to possess multi-scale fermenters, enabling it to produce both high-volume and low-volume fermentation-based products. This scale diversity also enables it to offer flexible CDMO services across various production volumes, including support for fermentation-based product development initiatives and complex injectables partners. The company has maintained a track record of regulatory adherence, having successfully completed 11 inspections from regulatory agencies and over 90 customers over the last three Fiscals, 2026. Notably, it has not received any critical observations from global regulators in course of their inspections during the last three Fiscals.

Continuous investment in R&D: Its innovation and an R&D-led development ethos have contributed to the growth of its operations and enabled it to build capabilities in industrial-scale steroidal and hormonal organic chemistry, as well as fermentation technologies across modalities ranging from bioconversion to biosynthesis and precision fermentation. Through continuous investment in R&D, it has evolved from a lab-scale manufacturer undertaking five to six step chemistry into an industrial-scale manufacturer with differentiated chemistry capabilities, enabling it to manufacture APIs and products collectively with up to 400 synthesis steps validated under cGMP efficiently. Its R&D capabilities support the development of complex, science and technology-based product offerings across APIs, fermentation-based products, complex injectables and drug–device combinations.

Robust financials with strong gross margins, high capital efficiency and cash conversion: The company has demonstrated a consistent track record of strong financial and operational performance. Its revenue from operations increased from Rs 7,162.47 million in Fiscal 2024 to Rs 7,515.54 million in Fiscal 2025 and further to Rs 8,691.49 million in Fiscal 2026, representing a CAGR of 10.16% between Fiscals 2024 and 2026, driven by robust global demand for its API products. Its high margin profile has been supported by a combination of improved product mix, increasing supplies to regulated markets, operational efficiencies, and controlled raw material prices. These factors have contributed to a significant improvement in its EBITDA margins, which increased from 24.48% in Fiscal 2024 to 27.26% in Fiscal 2025 and to 26.59% in Fiscal 2026, and it has already made investments into, and committed operational resources towards, its complex injectables and CDMO platform for future growth. Its financial performance and credit ratings reflect its disciplined financial management and prudent capital allocation practices.

Risks and concerns

High revenue concentration in API products: The company derives almost all of its revenue from the sale of APIs, which collectively constituted 96.07%, 99.10% and 100.00% of its revenue from operations in Fiscals 2026, 2025 and 2024, respectively. Further, its top five APIs constituted 62.27%, 63.16% and 60.37% of its revenue from operations in Fiscals 2026, 2025 and 2024, respectively. Any reduction in demand for APIs, and its top products in particular, or disruption in production, could have an adverse effect on its business, results of operations, financial condition and cash flows. Further, if its API production is interrupted due to equipment failure, supply chain disruptions, regulatory noncompliance, or other operational challenges, or if it fails to procure high-quality APIs in the quantities it requires on a cost-effective basis, the sales and distribution of its products could be delayed or interrupted.

Risks associated with export sales and overseas operations: The company exports its products to various countries, and its revenue from external customers outside India represented 67.04%, 55.19% and 59.97% of its revenue from operations in Fiscals 2026, 2025 and 2024, respectively. Its inability to manage the risks associated with its export sales could adversely affect its sales to customers in foreign countries, its results of operations, financial condition and cash flows. Further, as part of its overseas business operations, it may engage with government institutions and agencies in various jurisdictions. Such engagements expose it to risks including complex regulatory requirements, delays in decision-making, changes in government policies, and potential compliance challenges.

Dependence on top ten customers for revenue: The company derives a substantial portion of its revenue from certain key customers, including large pharmaceutical companies to whom it supplies products across multiple therapeutic categories. These customers rely on the company for consistent quality and timely delivery. Revenue generated from its top ten customers accounted for 57.59%, 55.90% and 61.65% of its revenue from sale of product in Fiscals 2026, 2025 and 2024, respectively. Loss of its relationship with any of these customers or delays or reductions in their orders could have an adverse effect on its business, results of operations, financial condition and cash flows. Further, since it does not maintain long-term contractual arrangements with its customers and rely on purchase orders, it is exposed to the risks of customer cancellations, delays, or order reductions, which could adversely affect its results of operations, financial condition and cash flows.

Supplier concentration and raw material supply chain risks: The company relies on securing timely supplies of raw materials for its manufacturing process. The company depends on certain suppliers for raw materials for its operations. Purchases from its top ten suppliers accounted for 25.50%, 18.41% and 50.33% of its total expenses in Fiscals 2026, 2025 and 2024, respectively. Any loss of such suppliers or non-performance of their obligations could adversely affect its business, results of operations, financial condition and cash flows. Its reliance on key suppliers presents several risks, including potential shortages of raw materials, increased costs, and reduced control over delivery schedules. Additionally, some suppliers may not have the capacity to handle sudden increases in orders for raw materials or may prioritise other customers over us. This uncertainty in its supply chain can result in increased costs as it may need to source materials at higher prices.

Outlook

Symbiotec Pharmalab is engaged in the business of manufacturing and selling of Active Pharmaceuticals Ingredientsvand Intermediates. It caters to both domestic and international markets. The company has a robust product portfolio of over 60 corticosteroid and steroidal-hormone APIs that are supplied globally, including Hydrocortisones, Betamethasones, Methylprednisolones, Progesterones, Estrogens and Testosterones, which are used extensively in critical care setups, as well as across chronic therapeutic areas such as respiratory, dermatology, pain management, oncology and gynaecology. On the concern side, the company procures a portion of its raw material requirements from different countries, including China and the United States. Any adverse developments in these countries, or the laws governing its imports from these countries, could disrupt its raw material supply and adversely affect its results of operations, financial condition and cash flows. further, it faces competition both within its API manufacturing business and in its role as a CDMO, which it has recently commenced. An inability to compete effectively may adversely affect its business, results of operations, financial condition and cash flows.

The issue has been offering 1,87,34,736 shares in a price band of Rs 938 -988 per equity share. The aggregate size of the offer is around Rs 1,757.32 crore to Rs 1,850.99 crore based on lower and upper price band respectively. Minimum application is to be made for 15 shares and in multiples thereon, thereafter. On performance front, its total income increased by 15.38% from Rs 7,559.79 million in Fiscal 2025 to Rs 8,722.58 million in Fiscal 2026. Its profit for the year was Rs 1,099.03 million in Fiscal 2026 compared to Rs 967.85 million in Fiscal 2025.

Meanwhile, in line with the R&D-focused ethos that has shaped its evolution, it intends to sustain and expand its innovation driven business model by consistently investing in technologies and strengthening its R&D infrastructure. For existing products, its focus will be on reducing manufacturing costs, and improving process efficiencies. Building on its track record of successfully developing complex molecules, such as conjugated estrogen products, it will continue to leverage its scientific expertise and integrated capabilities to address unmet global market opportunities. Its R&D ethos emphasises collaboration with global specialty pharmaceutical companies, academic institutions, and technology partners. It will also continue to invest in automation, digitalisation, and AI-driven process optimisation across its laboratories and manufacturing facilities to reinforce scalability, cost efficiency, and compliance with global regulatory standards, thereby accelerating its time to market.